Fintech

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Prnewswire·April 1, 2026 at 12:50 PM

/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Companies Balance AI Opportunities With Fear of Bubble
PYMNTS
Sona Secures $45 Million for AI Platform Expansion
PYMNTS
Tariffs Reshape Business Strategy One Year Later
PYMNTS
eToro launches crypto trading in New York
The Block

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Companies Balance AI Opportunities With Fear of Bubble

Sona Secures $45 Million for AI Platform Expansion

Tariffs Reshape Business Strategy One Year Later

eToro launches crypto trading in New York